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A B S T R A C T
Alpha-2-adrenoceptor agonists are sedatives that can cause fluctuations in serum insulin and blood
glucose (BG) concentrations in horses. The objectives of this study were to investigate the effects of
detomidine and vatinoxan on BG, insulin, and glucagon concentrations in horses with and without
insulin dysregulation (ID). In a blinded cross-over design, eight horses with ID and eight horses without
ID were assigned to each of four treatments: detomidine (0.02 mg/kg; DET), vatinoxan (0.2 mg/kg; VAT),
detomidine + vatinoxan (DET + VAT), and saline control (SAL). Blood samples were taken at 0,1, 2, 4, 6, and
8 h. Change from baseline was used as the response in modelling, and the differences between treatments
were evaluated with repeated measures analysis of covariance. P values 0.05 were considered
significant.
Comparing DET vs. SAL and DET vs. DET + VAT, insulin was higher at 2 h in the non-ID group and 2 and 4
h in the ID group. There was no difference in insulin between SAL and DET + VAT or VAT. Comparing DET
vs. SAL, BG was higher at 1 and 2 h then was lower at 4 h in both ID and non-ID groups. At 1 h in both
groups, BG after DET + VAT was lower than after DET but higher than after SAL. Comparing DET vs. SAL,
glucagon was lower at 1 h in the ID group and 1 and 2 h in the non-ID group. Vatinoxan was effective in
preventing detomidine-induced hyperglycaemia as well as the subsequent insulin increase in horses
with ID.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
An increase in plasma glucose concentration is induced by all
α2-adrenoceptor agonists commonly used for sedation in horses,
i.e. xylazine (Ringer et al., 2013; Kullmann et al., 2014; Kritchevsky
et al., 2020), detomidine (Kullmann et al., 2014; Tapio et al., 2018;
Kritchevsky et al., 2020), romifidine (Ringer et al., 2013; Kullmann
et al., 2014; Pakkanen et al., 2018) and medetomidine (Grimsrud
et al., 2012; Tapio et al., 2019). The increase is mediated by
activation of α2-adrenoceptors in pancreatic beta cells of the islets
of Langerhans, which inhibits insulin release (Angel et al., 1988).
The effects of α2-adrenoceptor agonists on plasma insulin
concentration have also been described in horses (Kritchevsky
et al., 2020). Furthermore, in horses with insulin dysregulation
(ID), after administration of xylazine, the initial decrease in insulin
concentration was followed by a marked increase, and the
hyperglycaemia was prolonged compared to control horses
without ID (Kritchevsky et al., 2020).
Vatinoxan (formerly MK-467 or L-659,066) is an α2-adrenoceptor
antagonist that minimally crosses the mammalian blood-brain
barrier (Clineschmidt et al., 1988; Honkavaara et al., 2020), so its
actions are predominantly on peripheral receptors (Clineschmidt
et al., 1988). Thus, the centrally mediated sedative effects of α2-
adrenoceptor agonists are not markedly affected (Vainionpää et al.,
2013; De Vries et al., 2016; Tapio et al., 2018, 2019), but peripheral
vasoconstriction and concomitant cardiovascular changes are
alleviated. This has been demonstrated in many species including
horses (De Vries et al., 2016; Tapio et al., 2018, 2019). Vatinoxan also
alleviates the glucose response to α2-agonists in horses (Pakkanen
et al., 2018; Tapio et al., 2018, 2019). In dogs, vatinoxan prevented
both the dexmedetomidine-induced decrease in plasma insulin
concentration and increase in glucose (Restitutti et al., 2012).
However, one study could not verify the effects of vatinoxan on
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J.R. Box, N.P. Karikoski, H.E. Tanskanen et al. The Veterinary Journal 269 (2021) 105610Activation of both α2- and β-adrenoceptors stimulate the
elease of glucagon by the alpha cells of the islets of Langerhans
Hirose et al., 1993). Glucagon increases plasma glucose concen-
ration by stimulating glycogenolysis and gluconeogenesis and it is
nhibited by elevated blood glucose (BG) concentrations (Iben Rix
t al., 2019). In the available literature, no studies on the effects of
2-adrenoceptor agonists or antagonists on plasma glucagon
oncentration in horses could be found, but in dogs, neither
exmedetomidine nor vatinoxan affected it significantly (Kallio-
ujala et al., 2018). Since it has been speculated that glucagon
roduction might be downregulated as a compensatory response
o hyperinsulinaemia in horses with ID (Newkirk et al., 2018),
irculating glucagon concentrations after administration of an α2-
drenoceptor agonist and/or antagonist were of interest to the
nvestigators.
The objectives of this study were to investigate the effects of an
2-adrenoceptor agonist (detomidine) and peripherally acting
ntagonist (vatinoxan) on plasma glucose, insulin, and glucagon
oncentrations in horses with normal and reduced insulin
ensitivity. It was hypothesised that vatinoxan would alleviate
he detomidine-induced alterations in blood glucose, insulin, and
lucagon concentrations but would not markedly affect them
hen administered alone.
aterials and methods
nimals and determination of insulin sensitivity
The study protocol was approved by the National Animal Experimentation
oard of Finland (Approval number, ESAVI/6728/04; Approval date, 10 July 2017).
Sixteen (5 geldings and 11 non-pregnant mares) adult Finnhorses 11.7  4 years
ld (mean  standard deviation) owned by the Natural Resources Institute Finland
r Equine College (Ypäjä, Finland) were selected for the study based on three
receding oral sugar tests (OST) conducted by the authors. Briefly, 29 horses were
sted overnight then given 0.45 mL/kg Karo Light corn syrup orally. Serum insulin
oncentration was measured before syrup and at 60, 90, and 120 min after
dministration. Horses were tested on three separate occasions (once each in June,
ugust, and October 2018). For this study, horses with insulin concentrations 40 m
/mL (Immulite 1000) at 60, 90,120, or all time points on at least one occasion were
lassified as ID (Durham et al., 2019). From the 29 horses, eight horses with low
sulin response (0–26.3 mIU/mL) and eight horses with ID were included in the
xperiment. Furthermore, horses were considered healthy based on physical exam
ndings, a haematological test, and a serum biochemical profile.
None of the horses had clinical signs consistent with pituitary pars intermedia
ysfunction. Plasma ACTH concentration of each horse was measured three times
June, August, October) before the experiments using a chemiluminescent immuno-
ssay (Immulite 1000) and all values were within the seasonally adjusted reference
ange. The seasonally adjusted ACTH cut-off concentrations used for the study were
4.5 pg/mL in June and 89.4 pg/mL in August and October (Adams et al., 2017).
est procedure
All horses were fasted overnight and throughout the entire experiment but had
ccess to water. Each horse was assigned to four treatments: saline control (SAL),
etomidine hydrochloride (HCl) (Equisedan 10 mg/mL, Vetcare Ltd.) (0.02 mg/kg)
DET), vatinoxan HCl (Vetcare Ltd.) (0.2 mg/kg) (VAT), and a combination of the
ame doses of detomidine HCl and vatinoxan HCl (DET + VAT) by means of a blinded
ross-over design with a minimum 13 day washout period between treatments.
orses’ weights were estimated using an equine weight tape (Virbac UK Ltd.).
atinoxan HCl powder was dissolved in saline to a concentration of 10 mg/mL.
etomidine and vatinoxan, or the same volume of saline, were mixed in the same
yringe immediately before administration. Each treatment was given as a single
olus via 18 G 1.3  32 mm IV catheter (Terumo Europe N.V.) after which the
atheter was removed.
lood sampling
mL serum tubes (Vacuette, Z serum clot activator, Greiner Bio-One) and was allowed
to clot at room temperature for at least 60 min. All plasma and serum samples were
centrifuged and separated within 4 h then stored at 80 C until analysis was
performed.
Sedation scoring
All horses were evaluated at 0, 0.5, 1, 2, 4, 6, and 8 h for sedation by one of two
investigators (JRB or HET) who were blinded to the treatments. Attitude, standing
ability, head position, eye openness, and ear position were scored then a total (0–10)
given at each time point (Rohrbach et al., 2009). A score of zero represented a fully
alert horse and a ten represented a deeply sedated but still standing horse.
Laboratory analysis
Insulin was analysed with an HI-14 K radioimmunoassay (Merck Millipore,
Missouri, USA) that has been validated for use in horses (Tinworth et al., 2011).
Glucagon was analysed with a GL-32 K radioimmunoassay (EMD Millipore), which
is not validated for use in horses according to the manufacturer. The coefficient of
variation of the solid controls varied between 1.1–10.3 % within day and 1.8–6.9 %
between days. The sensitivity of assay, as reported by manufacturer, was 18.5  2
pg/mL. All samples in both assays were measured in duplicate.
Statistical analysis
All statistical analyses were done using SAS System for Windows, version 9.4
(SAS Institute). Normality assumptions for all responses were checked with
Kolmogorov-Smirnov tests. For insulin and BG, normality could not be verified
initially. A logarithmic transformation was used on insulin values, and normality
was deemed adequate based on graphical inspection, skewness, and kurtosis values.
For BG, no transformation was found to normalise the distribution. The kurtosis
value was slightly larger than in normal distribution, but normality was considered
adequate for parametric analysis.
Pre-treatment measurement was used as a baseline, and the change was used as
the response in modelling. The differences between treatments were evaluated with
repeated measures analysisof covariance(RMANCOVA)models.The model included a
baseline covariate, the main effects (treatment, time point, ID status and period), two-
way-interactions (treatment*timepoint, treatment*ID-status, ID-status*timepoint,
period*timepoint), and three-way-interactions (treatment*ID-status*timepoint) as
fixed effects. Additionally, the main effect of horse, and two-way interactions of
horse*timepoint and horse*period as random effects were modelled. To verify the RM
ANCOVA results of BG, Wilcoxon signed rank sum test for treatment differences in
change from baseline in BG by timepoint and ID status was used.
The estimates of selected treatment effects by ID status were calculated over
time and by time point from the fitted analysis model with contrasts. Only
treatment comparisons to SAL and between DET and DET + VAT were of interest and
selected to be calculated. For the estimates, 95 % confidence intervals and P values
were calculated. P < 0.05 were considered statistically significant.
Results
Insulin
The mean serum insulin concentrations in response to each of
the four treatments are presented in Fig. 1a,b. The treatment effect
(P = 0.020) and the interaction of time point and treatment
(P < 0.0001) were both significant. No significant difference was
detected between the ID and non-ID groups. Fig. 2a illustrates the
individual variation in insulin concentrations after DET. Neither
DET + VAT nor VAT differed significantly in insulin concentration
from SAL at any time point in either group.
Blood glucose
Blood glucose concentrations in response to each of the four
treatments are shown in Fig. 1c,d. Again, the treatment effect
(P < 0.0001) and the interaction of time point and treatment
(P < 0.0001) were both found to be significant and no significantBlood samples to determine blood glucose (BG), plasma glucagon, and serum
sulin were taken before treatment and at 1, 2, 4, 6 and 8 h thereafter. Blood glucose
oncentration was determined from lithium-heparin blood (Vacuette LH, Greiner
io-One) immediately after sampling using a handheld glucometer (AlphaTRAK II,
oetis). Blood for glucagon concentration measurement was collected in 9 mL
2EDTA tubes (Vacuette K2EDTA, Greiner Bio-One) and kept cool until centrifuga-
ion (within 3 h). Blood for insulin concentration measurement was collected into 62
difference between groups was detected. The increase in BG was
less in both groups when comparing DET + VAT vs. DET at 1 and 2 h
(P < 0.0001). Four horses (2 in each group) at 4 h and one horse
with ID had BG values < 3.5 mmol/L at 6 h (confirmed with a
duplicate test). Fig. 2b illustrates the individual variation in BG
concentrations after DET.
J.R. Box, N.P. Karikoski, H.E. Tanskanen et al. The Veterinary Journal 269 (2021) 105610Fig. 2. Individual horse (n = 16) insulin (a) and blood glucose (b) response after detomidine (DET) treatment demonstrating interindividual variability in horses with insulin
dysregulation (ID; –x–) and without (non-ID; . . . o . . . ).
Fig. 1. Mean  standard deviation insulin (a,b), blood glucose (BG) (c,d), and glucagon (e,f) concentrations in horses with (left column, n = 8) and without (right column, n = 8)
insulin dysregulation (ID) after each treatment. Significant differences (P  0.05) in the change from baseline within each timepoint and compared to saline control (SAL) are
indicated by the symbols # for detomidine (DET), * for detomidine + vatinoxan (DET + VAT), and $ for vatinoxan (VAT). Significant differences between DET and DET + VAT are
indicated by @.Glucagon
Plasma glucagon concentrations in response to each of the four
treatments are shown in Fig. 1e,f. No significant difference between3
groups was detected, but treatmenteffect (P = 0.018) andthe interaction
of time point and treatment (P < 0.0001) were both found to be



























































J.R. Box, N.P. Karikoski, H.E. Tanskanen et al. The Veterinary Journal 269 (2021) 105610edation scoring
At 0.5 h after DET and DET + VAT, median (range) sedation score
as 6 (4–7) and 6 (3–7), respectively. Descriptive data are available
see Appendix A: Supplementary material).
iscussion
This study demonstrated that the α2-adrenoceptor antagonist
atinoxan can alleviate the detomidine-induced hyperglycaemia in
orses with and without ID, and it can prevent the subsequent
nsulin increase in horses with ID. Furthermore, when vatinoxan
as given alone, it did not significantly alter insulin or BG when
ompared to SAL. Lastly, vatinoxan was able to prevent the
eduction in plasma glucagon concentrations detected after DET.
In this study, insulin was initially decreased after DET, and a
oncurrent hyperglycaemia was detected. Although significance
ould only be detected in the non-ID group at 1 h, the insulin nadir
ay have occurred prior to the 1 h sample. It is also possible that
he delayed insulin clearance demonstrated in horses with ID (Tóth
t al., 2010) reduced the effect of DET on insulin concentration in
hat group. Yet in a recent study where samples were taken prior to
 h after detomidine, no significant decrease from baseline was
emonstrated in horses with and without ID (Kritchevsky et al.,
020). In another recent study, insulin was suppressed 10 min after
etomidine (Kerrigan et al., 2020). In our study, after this initial
ecrease, insulin concentrations significantly increased after DET
n the ID group until the 6 h sample. This prolonged increase could
e an exaggerated response to the increased BG. As revealed in this
tudy for the first time, vatinoxan prevented all the detomidine-
nduced fluctuations in insulin concentrations in plasma in horses
ith ID.
Detomidine induced a hyperglycaemia of similar magnitude in
orses with and without ID, which is supported by another study
Kritchevsky et al., 2020). After DET + VAT, BG was initially
ignificantly increased (compared to SAL) in both groups but the
agnitude and duration was markedly less than after DET.
imilarly, vatinoxan prevented detomidine-induced hyperglycae-
ia when administered with romifidine (Pakkanen et al., 2018).
urprisingly, at 4 and 6 h after DET, some horses in both groups
ecame hypoglycaemic (BG < 3.5 mmol/L) but none exhibited
linical sings. Only one of the four had an insulin concentration >
0 mIU/mL at these time points. Hypoglycaemia did not occur after
ny other treatments at any time point, and it is unclear at this time
hy it occurred.
Although activation of α2-adrenoceptors is reported to stimu-
ate glucagon excretion (Hirose et al., 1993) no such effect was
etected in our study. On the contrary, in both groups, there was
nitially a significant decrease in glucagon after DET, which
ppeared to coincide with the hyperglycaemia. Physiologically,
educed secretion of glucagon in response to hyperglycaemia was
o be expected (Iben Rix et al., 2019), so it remains unclear exactly
he extent to which α2- and β-adrenoceptors play a role in the
lucagon regulatory process in horses with and without ID.
The results of this study are potentially important because
orses are routinely sedated with detomidine and other α2-
drenoceptor agonists without knowledge of their insulin
egulation status. Furthermore, in the present study, the large
ndividual variation in insulin response makes it very difficult to
redict which horses will have exaggerated or prolonged insulin
induced an increase in BG that lasted for all the follow-up period,
namely during the infusion and at least 1 h after (Tapio et al.,
2019). No reports could be found on the effects of infusions with
an α2-adrenoceptor agonist on insulin concentration. On the other
hand, it is known that clinically normal ponies and horses develop
clinical laminitis when they have sustained hyperinsulinaemia for
approximately 48 h (Asplin et al., 2007; De Laat et al., 2010).
Therefore, it could be speculated that lengthy sedation with an α2-
adrenoceptor agonist could predispose some horses to a
prolonged hyperinsulinaemia and thus to laminitis. However,
more studies are needed to investigate the possible influence of
α2-adrenoceptor agonists on the risk of inducing laminitis. It
should be noted that the increased insulin demonstrated in this
study is unlikely to induce laminitis, although horses with greater
ID may be more significantly affected. Since vatinoxan alleviated
the detomidine-induced changes in insulin, BG, and glucagon in
both groups with no adverse effects, it could potentially be
beneficial to all horses that require sedation with detomidine
without the need to test for ID first.
The dose of detomidine used in this study was the labelled dose
to induce standing sedation in horses. The dose of vatinoxan used
was based on previous studies where it alleviated the cardiovas-
cular effects of detomidine in horses. Vatinoxan did not markedly
affect the sedative effects of detomidine which is similar to results
from previous studies (Vainionpää et al., 2013; Tapio et al., 2018).
The main limitation of this study was determination and
selection of the horses with ID. The ID status of the horses was
determined with the OST which may not be the most accurate test
for diagnosing ID (Dunbar et al., 2016). This may have allowed for
misclassification of the horses which could contribute to the large
variation in insulin response to detomidine particularly in the ID
group. Ideally the ID status would have been verified with a second
dynamic test such as an oral glucose test. Furthermore, the horses
without ID in this study were classified as non-ID in each of the
three OST performed, but not all horses with ID were classified as
ID every time. Annual variation in ID status has been demonstrated
in another study conducted by the authors (Box et al., 2019).
Therefore, it is possible that this also contributed to the variation in
insulin response after detomidine.
Conclusions
Vatinoxan at the dose used in this study prevented detomidine-
induced hyperglycaemia in horses with and without ID and the
subsequent serum insulin increase observed in horses with ID.
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